A Randomized, Controlled Study to Evaluate the Effect of Topically Applied BBI-2000 (5%) on Allergic Responses in Subjects With Contact Hypersensitivity to Diphencyprone

Trial Profile

A Randomized, Controlled Study to Evaluate the Effect of Topically Applied BBI-2000 (5%) on Allergic Responses in Subjects With Contact Hypersensitivity to Diphencyprone

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Jul 2017

At a glance

  • Drugs BBI-2000 (Primary)
  • Indications Contact dermatitis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Brickell Biotech
  • Most Recent Events

    • 13 Jul 2017 Status changed from active, no longer recruiting to completed.
    • 19 May 2017 Status changed from recruiting to active, no longer recruiting.
    • 29 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top